Agentix (AGTX) Stock Price, News & Analysis

Company Overview

Agentix, Inc. (OTCMKTS: AGTX) is a specialized provider of outsourced sales and marketing solutions for the life sciences, medical device, and pharmaceutical industries. The company offers a comprehensive suite of services that includes field agent management, territory planning, regulatory compliance support, and training programs for sales representatives. Leveraging a network of experienced independent contractors and proprietary technology platforms, Agentix delivers scalable solutions designed to help clients accelerate product launches, expand market reach and optimize customer engagement strategies. Key service offerings include turnkey field force deployment, call center operations, key opinion leader (KOL) outreach and multi-channel marketing support.

Central to Agentix’s value proposition is its proprietary CRM and analytics engine, which integrates real-time performance data, market insights and compliance tracking into a unified dashboard. This technology enables clients to monitor sales activities, assess territory performance and refine promotional tactics with data-driven precision. Additionally, the company provides digital engagement tools such as webinars, virtual product demos and e-detailing platforms, allowing pharmaceutical and medical device manufacturers to maintain high levels of customer interaction in both remote and hybrid environments. Agentix’s emphasis on quality management and regulatory adherence underpins its service delivery, ensuring that all field activities meet industry standards and local regulations.

Founded in 2005 and headquartered in Miami, Florida, Agentix has grown through a combination of organic expansion and strategic acquisitions. In 2015, the company expanded its European footprint with the acquisition of EuroPharm Sales Solutions, establishing offices in the United Kingdom and Germany. Today, Agentix operates across North America and Western Europe, serving a diverse client base that ranges from emerging biotech firms to multinational pharmaceutical corporations. The leadership team is led by CEO Sarah M. Jones, whose 20-year career in life-science sales and marketing has driven the development of Agentix’s global field-force infrastructure. Chief Financial Officer Robert T. Lee and Chief Technology Officer Alan P. Meyers round out the senior management team, bringing deep expertise in financial operations and technology innovation, respectively.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.02 to $0.05
• 52-Week Range: $0.02 to $0.46
• Volume: N/A
• Average Volume: 32,082 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AGTX Stock Analysis - Frequently Asked Questions

How have AGTX shares performed this year?

Agentix's stock was trading at $0.1775 on January 1st, 2025. Since then, AGTX shares have decreased by 83.4% and is now trading at $0.0295.

How do I buy shares of Agentix?

Shares of AGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Agentix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agentix investors own include E.On (EONGY), Burcon NutraScience (BRCN), BowX Acquisition (BOWX), Bionano Genomics (BNGO), Ballard Power Systems (BLDP), BlackBerry (BB) and

Company Calendar

• Today: 7/19/2025
• Next Earnings (Estimated): 9/22/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AGTX
• CIK: 1603345
• Web: fairwindenergyinc.com
• Phone: (321) 299-2014
• Fax: N/A
• Employees: 147,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A